联环药业 (600513)
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 28545.63
- Circulating A-Shares(W): 28545.63
- Earnings Per Share(RMB): -0.1200
- Net Assets Per Share(RMB): 4.6769
- Operating Revenue(W RMB): 208245.91
- Total Profit(W RMB): -149.72
- **Net Profit Attributable to Parent(W RMB) **: -3506.21
- Net Profit Growth Rate(%): -137.82
- Weighted Return on Equity(%): -2.5700
- Operating Cash Flow Per Share(RMB): -0.6060
- Undistributed Profit Per Share(RMB): 2.3987
- Capital Reserve Per Share(RMB): 0.9106
2. Main Business
The main business covers:
- Research, development, production, and sales of chemical pharmaceuticals
3. Company Basic Information
- Company Name: Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- Listing Date: 2003-03-19
- Industry: Pharmaceutical Manufacturing
- Address: No. 9, Health Road, Yangzhou Bio-Health Industrial Park, Jiangsu Province
- Website: https://www.lhpharma.com/
- Company Profile: The company's main promoter, Yangzhou Pharmaceutical Factory, was established in 1958 as a large national comprehensive pharmaceutical enterprise. In December 1999, approved by the Jiangsu Provincial People's Government, the company was jointly established by Yangzhou Pharmaceutical Factory as the main promoter, along with Shanghai United Venture Investment Co., Ltd., China National Medicines Corporation Ltd., Jiangsu Property Management Co., Ltd., and Suzhou Industrial Park Pharmaceutical University New Drug Development Center Co., Ltd.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Jiangsu Lianhuan Pharmaceutical Group Co., Ltd. | General Legal Person | 11388.48 | 39.90 |
| 2 | China National Medicines Corporation Ltd. | General Legal Person | 375.21 | 1.31 |
| 3 | UBS AG | QFII | 198.26 | 0.69 |
| 4 | J. P. Morgan Securities PLC - Proprietary Funds | QFII | 132.98 | 0.47 |
| 5 | CITIC Securities Asset Management (Hong Kong) Limited - Client Funds | Asset Management Plan | 121.92 | 0.43 |
| 6 | BARCLAYS BANK PLC | QFII | 83.27 | 0.29 |
| 7 | Goldman Sachs & Co. LLC | General Legal Person | 78.44 | 0.27 |
| 8 | MORGAN STANLEY & CO. INTERNATIONAL PLC. | QFII | 74.76 | 0.26 |
5. Concept Sectors
- Innovative Drugs
Remarks
- Data update date: 2025-10-31
- Data source: Public market information